Recent Company News

• 11:42 AM ET Nov 06, 2025
  

  Bayer AG CFO Wolfgang Nickl to step down in 2026; Judith Hartmann appointed new CFO (€26.42, 0.00)

• 09:04 AM ET Nov 06, 2025
  

  Bayer AG announces KERENDIA (finerenone) meets primary endpoint in Phase III clinical trial for adults with Type 1 diabetes and chronic kidney disease (€26.20, -0.23)

• 11:36 AM ET Oct 31, 2025
  

  Bayer, drug distributors see legacy liability revived as courts reconsider claims in litigation developments (31-Oct)

• 08:26 AM ET Oct 31, 2025
  

  StreetAccount Themes Headlines (31-Oct)

• 01:25 PM ET Oct 30, 2025
  

  Bayer notes Washington Supreme Court ruling in Erickson vs Monsanto (€26.87, 0.00)

• 01:32 PM ET Oct 24, 2025
  

  Bayer AG issues press release on previously disclosed FDA approval of Lynkuet (elinzanetant) to treat hot flashes; expected to be available in the U.S. beginning in November 2025 (€27.78, 0.00)

• 01:13 PM ET Oct 24, 2025
  

  FDA approves Bayer's Lynkuet (elinzanetant) to treat hot flashes (€27.78, 0.00)

• 08:53 AM ET Oct 23, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:16 PM ET Oct 23, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market